Plain-English translation of NCT02302742 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Researchers are building a registry—a database of patient information—to understand the link between inherited genetic mutations and triple negative breast cancer. This study focuses on people diagnosed with triple negative breast cancer and those who carry genes linked to hereditary breast and ovarian cancer (like BRCA, PTEN, or P53). By collecting information about your medical history, genetic testing results, and how your cancer has progressed, researchers hope to improve how doctors understand and treat these cancers in the future.
Triple negative breast cancer can be aggressive and harder to treat than other types. Researchers believe that understanding which genetic mutations are present in patients with this disease could help develop better treatments and improve outcomes. This study exists to create a large database of information that researchers can study to find these connections.
You likely qualify if…
You likely don't qualify if…
Participation in this study involves sharing your medical information—such as your cancer diagnosis details, pathology reports, genetic test results, and family history—with the research team. There are no medications to take or procedures to undergo. You may be asked to provide a blood or tissue sample for the registry, and the study team will track your health information over time to see how your cancer progresses. This is a non-interventional study, meaning researchers are observing and collecting data rather than testing a new treatment.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
United States